JP4191255B2 - ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 - Google Patents

ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 Download PDF

Info

Publication number
JP4191255B2
JP4191255B2 JP53641598A JP53641598A JP4191255B2 JP 4191255 B2 JP4191255 B2 JP 4191255B2 JP 53641598 A JP53641598 A JP 53641598A JP 53641598 A JP53641598 A JP 53641598A JP 4191255 B2 JP4191255 B2 JP 4191255B2
Authority
JP
Japan
Prior art keywords
protein
chemokines
virus
cells
chemokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP53641598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513629A5 (https=
JP2001513629A (ja
Inventor
スミス，ジェフリー
ング，アイルウィン
Original Assignee
オックソン セラピュティックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9703592.7A external-priority patent/GB9703592D0/en
Priority claimed from GBGB9800113.4A external-priority patent/GB9800113D0/en
Application filed by オックソン セラピュティックス リミテッド filed Critical オックソン セラピュティックス リミテッド
Publication of JP2001513629A publication Critical patent/JP2001513629A/ja
Publication of JP2001513629A5 publication Critical patent/JP2001513629A5/ja
Application granted granted Critical
Publication of JP4191255B2 publication Critical patent/JP4191255B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP53641598A 1997-02-21 1998-02-23 ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質 Expired - Fee Related JP4191255B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9703592.7A GB9703592D0 (en) 1997-02-21 1997-02-21 Poxvirus chemokine-binding protein
GB9703592.7 1998-01-05
GBGB9800113.4A GB9800113D0 (en) 1998-01-05 1998-01-05 A soluble vaccinia virus protein that binds chemokines
GB9800113.4 1998-01-05
PCT/GB1998/000569 WO1998037217A1 (en) 1997-02-21 1998-02-23 A soluble vaccinia virus protein that binds chemokines

Publications (3)

Publication Number Publication Date
JP2001513629A JP2001513629A (ja) 2001-09-04
JP2001513629A5 JP2001513629A5 (https=) 2004-12-09
JP4191255B2 true JP4191255B2 (ja) 2008-12-03

Family

ID=26311039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53641598A Expired - Fee Related JP4191255B2 (ja) 1997-02-21 1998-02-23 ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質

Country Status (7)

Country Link
US (3) US6355252B1 (https=)
EP (2) EP0985046B1 (https=)
JP (1) JP4191255B2 (https=)
AT (1) ATE323170T1 (https=)
AU (1) AU749921B2 (https=)
DE (1) DE69834179T2 (https=)
WO (1) WO1998037217A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985046B1 (en) * 1997-02-21 2006-04-12 Oxxon Therapeutics Limited Recombinant poxvirus incapable of expressing a41l gene, coding for a soluble protein that binds chemokines
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO2002080948A1 (en) * 2001-04-05 2002-10-17 The Trustees Of Princeton University Compositions and methods for treating inflammation and related conditions
AU2002346056A1 (en) * 2001-07-12 2003-01-29 Immunex Corporation Viral proteins capable of binding lar
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030077247A1 (en) * 2001-09-20 2003-04-24 Schering Corporation Chemokines as adjuvants of immune response
AU2003259117A1 (en) * 2002-07-10 2004-01-23 The Regents Of The University Of California Antimicrobial activity of interferon-inducible elr chemokines
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
US20100189747A1 (en) * 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US20070160571A1 (en) * 2006-01-11 2007-07-12 Mitchell Krathwohl Composition and method for inducing protective vaccine response
WO2006076383A2 (en) * 2005-01-11 2006-07-20 Rosetta Stone Labs, Llc Composition and method for inducing a protective vaccine response
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
JP2009510102A (ja) * 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション 免疫調節組成物およびその使用
PL2005185T3 (pl) 2006-03-22 2011-05-31 Viral Logic Systems Tech Corp Sposoby identyfikowania celów polipeptydowych
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US8263064B2 (en) 2007-06-04 2012-09-11 Rappaport Family Institute For Research In The Medical Sciences Method of suppressing disease severity of multiple sclerosis using chemokine CXC11
WO2009082594A2 (en) 2007-11-26 2009-07-02 Fox Chase Cancer Center Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
BR112012005774B8 (pt) 2009-09-14 2023-02-14 Jennerex Inc uso de um inibidor de quinase antiangiogênico no tratamento de câncer
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2218499C (en) * 1995-04-19 2007-02-20 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
WO1998036766A1 (en) * 1997-02-21 1998-08-27 Isis Innovation Limited Anti-hiv protein
EP0985046B1 (en) * 1997-02-21 2006-04-12 Oxxon Therapeutics Limited Recombinant poxvirus incapable of expressing a41l gene, coding for a soluble protein that binds chemokines
JP2001168323A (ja) * 1999-12-06 2001-06-22 Mitsubishi Electric Corp 半導体装置の製造方法

Also Published As

Publication number Publication date
US20020071849A1 (en) 2002-06-13
EP0985046B1 (en) 2006-04-12
DE69834179D1 (de) 2006-05-24
US20040142002A1 (en) 2004-07-22
US6355252B1 (en) 2002-03-12
DE69834179T2 (de) 2007-02-01
ATE323170T1 (de) 2006-04-15
EP1405916A1 (en) 2004-04-07
EP0985046A1 (en) 2000-03-15
US7384643B2 (en) 2008-06-10
AU6302098A (en) 1998-09-09
AU749921B2 (en) 2002-07-04
WO1998037217A1 (en) 1998-08-27
JP2001513629A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
JP4191255B2 (ja) ケモカイン類に結合する可溶性ワクシニアウイルスタンパク質
Alcami et al. A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection
Barry et al. The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes
JP4077876B2 (ja) ケモカイン結合タンパク質およびその使用
JPH05503282A (ja) 乳頭腫ウイルス誘発腫瘍の予防及び治療のための薬理組成物
Xiang et al. Identification of human and mouse homologs of the MC51L–53L–54L family of secreted glycoproteins encoded by the Molluscum contagiosum poxvirus
JPH11507224A (ja) ヒトケモカインβ−１１およびヒトケモカインα−１
EP0555291A1 (en) Vaccinia vectors, vaccinia genes and expression products thereof
JP2000507101A (ja) ケモカインアルファ２
Chen et al. Analysis of host response modifier ORFs of ectromelia virus, the causative agent of mousepox
JPH11512610A (ja) 短縮形ケモカインβ−８
AU2002301315B2 (en) A soluble vaccinia virus protein that binds chemokines
US7186408B2 (en) Viral CD30 polypeptide
RU2405824C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pFastBac-B17R, СОДЕРЖАЩАЯ ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КОРОВ, КОДИРУЮЩИЙ АЛЬФА/БЕТА-ИНТЕРФЕРОНСВЯЗЫВАЮЩИЙ БЕЛОК И ШТАММ БАКУЛОВИРУСА BvB17RG, ПРОДУЦИРУЮЩИЙ РАСТВОРИМЫЙ АЛЬФА/БЕТА-ИНТЕРФЕРОНСВЯЗЫВАЮЩИЙ БЕЛОК ВИРУСА ОСПЫ КОРОВ
EP0656949A1 (en) Vaccinia virus b15r used in interleukin b1-involving condition
RU2630672C1 (ru) Рекомбинантный штамм VV-GMCSF/lact-dGF вируса осповакцины, обладающий онколитической активностью и продуцирующий секретируемый химерный белок, состоящий из гранулоцитарно-макрофагального колониестимулирующего фактора человека и онкотоксического белка лактаптина
WO1998036766A1 (en) Anti-hiv protein
CN116655780A (zh) 一种广谱中和SARS-CoV-2的中和抗体P5S-2A9及其应用
WO1999020652A1 (en) Feline granulocyte colony-stimulating factor
Smith Manipulation of the chemokine system by poxviruses
WO1998007862A2 (en) Chemokine beta-16
Xu Characterization of the role of myxoma viral protein M-T2 in the inhibition of apoptosis.
US20090110694A1 (en) Anti-Inflammatory Proteins and Improved Vaccines
JP2003024089A (ja) ヒト腫瘍壊死因子受容体
JPH02156883A (ja) 組み換えワクチニアウイルス

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040316

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061101

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080902

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080918

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110926

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees